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Abstract In PC12 cells, cAMP stimulates the MAP kinase 
pathway by an unknown mechanism. Firstly, we examined the 
role of calcium ion mobilization and of protein kinase C in cAMP- 
stimulated MAP kinase activation. We show that cAMP stimu- 
lates p44 mapk independently of these events. Secondly, we studied 
the role of B-Raf in this process. We observed that NGF, PMA 
and cAMP induce the phosphorylation of B-Raf as well as an 
upward shift in its electrophoretic mobility. We show that B-Raf 
is activated following NGF and PMA treatment of PC12 cells, 
and that it can phosphorylate and activate MEK-1. However, 
cAMP inhibits B-Raf autokinase activity as well as its ability to 
phosphorylate and activate MEK-1. This inhibition is likely to be 
due to a direct effect since we found that PKA phosphorylates 
B-Raf in vitro. Further, we show that B-Raf binds to p21 ras, but 
more important, this binding to p21 ras is virtually abolished with 
B-Raf from PCI2 cells treated with CPT-cAMP. Hence, these 
data indicate that the PKA-mediated phosphorylation of B-Raf 
hampers its interaction with p21 ras, which is responsible for the 
PKA-mediated decrease in B-Raf activity. Finally, our work sug- 
gests that in PC12 cells, cAMP stimulates MAP kinase through 
the activation of an unidentified MEK kinase and/or the inhibition 
of a MEK phosphatase. 
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1. Introduction 
MAP kinases are key elements in the transduction of a large 
variety of extracellular stimuli (growth factors, hormones, neu- 
rotransmitters), which activate diverse signaling systems in the 
cell. Initial events in the various pathways include stimulation 
of tyrosine protein kinases, elevation of intracellular calcium, 
and activation of protein kinase C. Several signaling circuitries 
leading to MAP kinase activation converge on Ras, which leads 
to the sequential ctivation of Raf-l, MEKs and MAP kinases 
[1,2]. 
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Abbreviations: MAP kinase, mitogen-activated protein kinase; MEK, 
MAP kinase or ERK kinase; CPT-cAMP, 8-(4-chlorophenylthio)-cy- 
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PMA, phorbol 12-myristate 13-acetate; PKA, cAMP-dependent pro- 
tein kinase; PKC, protein kinase C. 
We have previously reported that in the neuroendocrine 
PC12 cells cAMP activates MAP kinase and potentiates the 
stimulating effects of other agents [3]. The stimulatory effect of 
cAMP was observed also on MEK, but no further information 
is available on the mechanism used by cAMP in these cells. In 
contrast o PC12 cells, in smooth muscle cells [4], adipocytes 
[5] and some fibroblast cell lines [6,7], cAMP inhibits the MAP 
kinase cascade. In these cells it has been shown that cAMP- 
dependent protein kinase (PKA) phosphorylates Raf- 1, render- 
ing it less efficient in interacting with Ras [8 10]. The appar- 
ently cell-specific modulation of MAP kinase by cAMP is of 
considerable interest, since the biological action of cAMP in the 
different cell types is coherent with its action on the MAP 
kinase pathway. Indeed, in PC12 cells, cAMP stimulates the 
MAP kinase pathway and the key biological effect in these cells, 
i.e. neuronal differentiation [3]. In contrast, it decreases biore- 
sponses in cells in which it inhibits the MAP kinase cascade 
[4-73. 
To elucidate how cAMP may affect the MAP kinase route 
in PC12 cells, we firstly investigated the PKC- and calcium- 
dependence of this response. Secondly, we looked at B-Raf 
phosphorylation a d activation, and its possible role as a kinase 
upstream of MEK. In contrast to the ubiquitous Raf-1, B-Raf 
is abundant in only a few tissues, such as neuronal cells and 
PCI2 cells [11,12]. We show that exposure of PC12 cells to 
NGF, PMA and cAMP induces B-Raf phosphorylation. Fur- 
thermore, NGF treatment increases B-Raf autokinase activity 
but this is inhibited by cAME Importantly, in a reconstitution 
assay, B-Raf can phosphorylate and activate MEK-1. B-Raf 
activity is stimulated following NGF and PMA treatment of 
PC12 cells, but after cAMP co-treatment these activations re- 
turned to basal evels. Next, we show that PKA phosphorylates 
B-Raf in vitro. Moreover, B-Raf from untreated PC12 cells 
associates with p21 ra~, but treatment of these cells with CPT- 
cAMP decreased the ability of B-Raf to associate with p21 r"s. 
It is therefore likely that PKA-mediated phosphorylation f 
B-Raf reduces its ability to interact with p21 ras, explaining the 
reduced activation of B-Raf in CPT-cAMP-treated PC12 cells. 
Our results indicate that, while B-Rafcan function as a MEK 
kinase, it does not appear to be actively implicated in the 
cAMP-induced stimulation of the MAP kinase pathway in 
PC12 cells. 
2. Materials and methods 
2.1. Materials 
Antibodies to p44 mapk [13], MEK-1 [3] were obtained as previously 
described. Antibodies to B-Raf were generated against apeptide corre- 
sponding to exon 11 of the Rmil protein [14], the avian homologue of 
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the B-Raf gene product, which also recognize murine B-Raf protein 
(Barnier et al., unpublished results). The PKA catalytic subunit, PKI, 
and MBP were from Sigma. Activated CH Sepharose 4B was from 
Pharmacia. 
2.2. Cell culture 
PC12 cells were cultured in RPMI 1640 supplemented with 10% 
horse serum and 5% fetal calf serum. Prior to stimulation, cells were 
starved overnight in RPMI 1640 containing 0.25% fetal calf serum and 
0.2% bovine serum albumin. 
2.3. p44 m"pk assay 
p44 mark activity was measured in an immune complex kinase assay 
as described [3]. Briefly, cells were solubilized in stop buffer (50 mM 
HEPES, pH 7.5, 10 mM EDTA, 150 mM NaCI, 10 mM Na4P207, 2 mM 
sodium orthovanadate, 100 mM NaF, 1% Triton X-100 (v/v), 100 U/ml 
aprotinin, 20 mM leupeptin, and 0.18 mg/ml PhMeSO2F). p44 mapk was  
immunopurified from cell extracts with antibody preabsorbed to pro- 
tein A-Sepharose, and its kinase activity measured by incubation with 
[yJ2P]ATP and myelin basic protein as a substrate. Radioactivity incor- 
porated in myelin basic protein was quantitated by spotting an aliquot 
of the kinase reaction mixture onto phosphocellulose paper, followed 
by washing, and determination f the radioactivity associated with the 
papers. 
2.4. s2p labeling 
PCI2 cells were incubated in serum- and phosphate-free RPMI, 
containing 0.5 mCi/ml [32p]orthophosphate for 3.5 h. Thereafter, cells 
were stimulated, solubilized in stop buffer and cell extracts were im- 
munoprecipitated with antibody preadsorbed to protein A-Sepharose. 
Immunopurified proteins were subjected to SDS-PAGE analysis under 
reducing conditions followed by autoradiography. 
2.5. B-Raf autokinase assay 
After starvation, PC12 cells were treated with the indicated com- 
pounds and lysed in stop buffer. Cell extracts were immunopurified 
using an antibody to B-Raf preadsorbed to protein A-Sepharose. Im- 
munopurified proteins were then incubated in kinase buffer (20 mM 
HEPES, pH 7.4, 10 mM MgCl2, 1 mM DTT, 40 mM pNPP) and 
autokinase activity was initiated by addition of 1 pM [y-32p]ATP (7000 
Ci/mmol). After 10 min at room temperature the reaction was stopped 
by addition of Laemmli buffer and proteins were subjected to SDS- 
PAGE analysis on a 7.5% resolving el. 
2.6. B-Raf activity towards' MEK-1 
B-Raf was immunopurified asdescribed above and incubated in the 
presence or absence of immunopurified MEK-1 in kinase buffer supple- 
mented with 1 pM [y-32p]ATP (7000 Ci/mmol). After 10 min at room 
temperature, the kinase reaction was stopped by addition of Laemmli 
buffer and proteins were subjected to SDS-PAGE analysis on a 10% 
resolving el. MEK-1 was immunopurified from CHO cells transfected 
with an expression vector coding for human MEK-I. 
2.7. MEK-1 activation mediated by B-Raf 
After the appropriate treatment, PC12 cells were lysed in stop buffer 
and B-Raf was immunopurified as described above. B-Raf was then 
incubated with or without immunopurified MEK-1 in kinase buffer 
enriched with 15 pM ATE After 10 min, recombinant p44 mapk was 
added or not for 10 rain, then 1 pM [y-32p]ATP (7000 Ci/mmol) and 
150 pg/ml myelin basic protein were added for 10 min. Proteins were 
subjected to SDS-PAGE analysis on a 12.5% resolving el and autora- 
diographed. 
2.8. PKA-mediated B-Raf phosphorylation 
B-Raf was immunoprecipitated from PC 12 cells, thereafter incubated 
in kinase buffer supplemented with 50/IM ATP for 15 min. Pellets were 
washed and incubated in HEPES 30 mM, pH 7.4, 30 mM NaCI, Triton 
X-100 0.1% (v/v), 100 mM NaF and 0.1/~M okadaic acid, and treated 
or not with PKA catalytic subunit (10 U) and PKI (10 ng); thereafter 
a mixture containing 8 mM MgCI2, 4 mM MnC12, and 15 ,uM 
[y-32p]ATP (100 Ci/mmol) was added. After 10 min at room tempera- 
ture the reaction was stopped by the addition of Laemmli buffer, and 
proteins were subjected to SDS-PAGE analysis on a 7.5% resolving el. 
2.9. Association of B-Raf with p21 n" . . . . . .  
Recombinant p21H ..... was immobilized on Sepharose beads. There- 
after, p21" ..... was complexed with GDP, or with the non-hydrolysable 
GTP analogue, GTPyS, by incubating the p21H ..... beads with GDP 
(100,uM) or GTPTS (100 pM) for 30 min at 37°C in 50 mM HEPES, 
pH 7.5, 2 mM EDTA. Control experiments were performed using 
heat-denaturated p21Ha-r,s. The beads (corresponding to approximately 
300 pg of p21m-r"~) were incubated for 3 h at 4°C with 3 mg of extracts 
from untreated PC12 cells or PC12 cells treated for 15 min with 1 mM 
CPT-cAMP. Cell extracts were obtained as described above except hat 
the stop buffer lacked EDTA. After 4 washes in stop buffer supple- 
mented with 0.1% SDS, the proteins associated with p21H ..... were 
eluted in Laemmli buffer and subjected to Western blot analysis using 
B-Raf as a probe. 
3. Results and discussion 
In contrast o observations made in several other cell types 
(smooth muscle cells [4], adipocytes [5] and fibroblasts [6,7]), we 
have previously reported that, in PC12 cells, cAMP activates 
MAP kinase (p42 mapk and p44 mapk) and MEK- I  [3]. While the 
inhibitory effect of cAMP has been shown to be induced 
through PKA-mediated Raf- 1 phosphorylat ion [9,10,15], noth- 
ing is known about the mechanism underlying the stimulatory 
action of cAMP on MAP kinase, cAMP is known to exert most 
of its biological effects by means of PKA, but it has also been 
shown to modulate directly the Glut  4 transporter [16] and 
some ion channels [15,17,18]. Thus it is possible that in PC12 
cells the stimulatory effect of cAMP on MAP kinase could 
result from a cross-talk with other second messengers, in partic- 
ular calcium ions or PKC, which are known to stimulate MAP 
kinase activity in several cell types [19,20]. To investigate 
whether cAMP might feed into the MAP kinase cascade by 
mobil izing extracellular calcium or by activating protein kinase 
C, we tested the effects of chelating extracellular calcium and 
of down-regulation of PKC by overnight incubation of PCI 2 
cells with PMA (Fig. 1). Neither EGTA nor down-regulation 
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Fig. 1. Effects of EGTA and of preincubation with PMA on p44 mapk 
activation by cAMP in PC 12 cells. Cells were treated with buffer (open 
bars), incubated with 5 mM EGTA (hatched bars), or incubated over- 
night with 1 pM PMA (solid bars). One hour before the stimulation 
PMA was removed by two washes. Cells were then exposed for 15 min 
to 1 mM CPT-cAMP, 1 /~M PMA or 50 nM NGF or for 10 min to 
1 pM ionomycin and thereafter solubilized, p44 mapk was immunoprecip- 
itated and its kinase acitivity was measured as described in section 2. 
p44 mapk activity is expressed as fold-stimulation above the level seen in 
untreated cells. Data represent the mean+S.D, of triplicate wells from 
an experiment performed twice with similar results. 
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Fig. 2. B-Raf phosphorylation in PC12 cells. (A) In vivo 32p labeling. 
32p-Loaded PC12 cells were incubated for 15 min with 1 mM CPT- 
cAME 1/.tM PMA, CPT-cAMP plus PMA, 0.1/IM NGF and CPT- 
cAMP plus NGF and solubilized. B-Raf was then immunopurified and 
subjected to SDS-PAGE analysis. This autoradiograph is representa- 
tive of an experiment performed twice. (B) B-RafWestern blot analysis. 
PC12 were incubated for 15 min with 1 mM CPT-cAMR 1 ,uM PMA, 
0.1 ¢tM NGF, and CPT-cAMP together with PMA or NGF, and 
solubilized. Proteins were separated by SDS-PAGE and transferred to
a nitrocellulose membrane which was probed with an antibody to B- 
Raf. The membrane was incubated with ~25I-labelled protein A and 
autoradiographed. This autoradiograph is representative of an experi- 
ment performed three times with comparable r sults. 
of PKC inhibited MAP kinase activation by CPT-cAMP, a 
membrane-permeant cAMP analogue. Chelation of intracellu- 
lar calcium by BAPTA was also without effect (results not 
shown). Furthermore, no rise in intracellular calcium was ob- 
served with a calcium probe in CPT-cAMP-treated PC12 cells. 
As reported by others [21], the NGF-induced MAP kinase 
activation was inhibited by 30% upon calcium chelation, but 
was unaffected by PKC down-regulation. I  PC 12 cells exposed 
to NGF and CPT-cAMP, CPT-cAMP increased NGF-stimu- 
lated MAP kinase activity by approximately 40% [3]. As found 
in cells treated with NGF only, this activation is inhibited by 
20% after calcium chelation, and not significantly modified 
after PKC down-regulation. Confirming the efficiency of PKC 
down-regulation, we found that PMA pretreatment totally 
abolished MAP kinase activation by PMA. PKC down-regula- 
tion was also shown to partially inhibit he effect of ionomycin, 
a calcium ionophore. Confirming efficient chelation of extracel- 
lular calcium, EGTA abolished completely MAP kinase activa- 
tion by ionomycin. These findings indicate that cAMP activates 
MAP kinase independently of calcium mobilization and of 
stimulation of a PMA-sensitive PKC. 
We then tried to determine at which step, upstream of MAP 
kinase, the stimulatory effect of cAMP is initiated. Firstly, we 
determined whether PKA was able to phosphorylate MEK. To 
do this, we performed an in vitro kinase assay using recombi- 
nant GST-MEK-1 or GST-MEK-2, and purified PKA catalytic 
subunit. In these experiments, we were unable to detect PKA- 
mediated phosphorylation f either of the MEK proteins (data 
not shown). However, since MEK-1 and MEK-2 do not con- 
tain canonical consensus PKA phosphorylation sites, these re- 
sults are not surprising. We then looked at a potential upstream 
activator of MEK. While Raf-1 has been shown to activate 
MEK, a similar function of B-Raf has not been clearly docu- 
mented. In contrast to the ubiquitously expressed Raf-1, B-Raf 
is abundant inonly a few tissues, including neuronal tissue and 
PC12 cells [11,12]. It could therefore confer cell type specificity 
with respect to the regulation of the MAP kinase cascade. PC12 
cells were loaded with [32p]orthophosphate, treated with appro- 
priate compounds and B-Raf was immunoprecipitated with a 
specific antibody. As observed in Fig. 2A, CPT-cAMP in- 
creased the phosphorylation f B-Raf (2-fold above the level 
observed in untreated cells). PMA also induced B-Raf phos- 
phorylation (2.5-fold), which is slightly increased (3-fold) after 
a co-treatment with CPT-cAMP. NGF alone increased B-Raf 
phosphorylation (3-fold), and this phosphorylation is ot mod- 
ified after a CPT-cAMP co-treatment. The phosphorylation 
was linked to an upward shift in electrophoretic mobility as 
observed by Western blot analysis of B-Raf (Fig. 2B). We then 
looked to see whether the PKA-mediated phosphorylation f 
B-Raf modified its autokinase activity, and whether B-Raf 
could phosphorylate MEK. To do this, PC12 cells were treated 
for 10 or 60 min with CPT-cAMP, NGF or both and then lysed. 
B-Raf was immunoprecipitated from the cell extracts and its 
autokinase activity was measured as described in section 2. As 
shown in Fig. 3, NGF augmented the autokinase activity of 
200 
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Treatment :  10 min 60 min  
Fig. 3. B-Raf autokinase assay. PC12 cells were incubated for 10 or 60 
min with 0.1/.tM NGF, 1 mM CPT-cAMP, or NGF with CPT-cAMP 
and solubilized. B-Raf was then immunopurified, submitted to an 
autokinase assay, as described insection 2, analyzed by SDS-PAGE on 
a 7.5% resolving el and autoradiographed. This autoradiograph is 
representative of an experiment performed twice with comparable r - 
sults. 
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Fig. 4. MEK-I phosphorylation by B-Raf. PC12 cells were incubated for 15 min with 0.1 #M NGF, 1 mM CPT-cAMP, CPT-cAMP with NGF, 
1 pM PMA and PMA with CPT-cAME B-Raf was immunoprecipitated from these cells and incubated in presence or in absence of immunopurified 
MEK-1 as described in section 2. The results have been quantified by scanning densitometry, and are expressed as means + S.E.M. (n = 3-4) of B-Raf 
activity above basal (left panel). This autoradiogaph is representative of 3-4 experiments which gave comparable results. 
B-Raf, and this increase was inhibited by a CPT-cAMP co- 
treatment. Interestingly, these results show that, as observed 
for Raf- 1 [22], the upward B-Raf shift in electrophoretic mobil- 
ity can not be linked to a change in its kinase activity. To 
determine whether the autokinase activity of B-Raf correlates 
with its ability to activate MEK-1, PC12 cells were treated with 
CPT-cAMP, PMA and NGF,  and then the kinase activity of 
B-Raf towards MEK-1 was measured as described in section 
2. As illustrated in Fig. 4, NGF stimulated the B-Raf-mediated 
phosphorylation of MEK-1 by 2.5 + 0.2-fold over basal. PMA 
was also able to activate B-Raf, albeit with lower efficiency than 
NGF (1.7 + 0.l-fold over basal). CPT-cAMP alone had no 
effect on B-Raf activity (1.1 + 0.1-fold over basal). Strikingly, 
we found that CPT-cAMP inhibits B-Raf activation induced 
either by NGF (from 2.5 + 0.2 to 1.35 + 0.1), or by PMA (from 
1.7 + 0.1 to 1.1 + 0.1). Western blot experiments performed 
after B-Raf immunoprecipitation from cells treated with these 
compounds revealed that the amount of B-Raf immunoprecip- 
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Fig. 5. MEK-1 activation mediated by B-Raf. PC12 cells were incubated for 15 min with 0.1 pM NGF, 1 mM CPT-cAMP and CPT-cAMP with 
NGF. B-Raf was immunopurified from these cells and incubated or not with immunopurified MEK-1 in the presence of unlabeled ATP for 10 min. 
Recombinant p44 mapk was then added for 10 min followed by a 10 min incubation with [T-32p]ATP and myelin basic protein. Proteins were then 
subjected to SDS-PAGE analysis on a 12.5% resolving el and autoradiographed. 
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Fig. 6. PKA-mediated B-Raf phosphorylation. B-Raf was immunopu- 
rifled from PC12 cells, thereafter incubated inthe presence ofATP and 
then treated with buffer alone, PKA or PKA together with PKI for 
10 min, as described in section 2. Proteins were then subjected to 
SDS-PAGE analysis on a 7.5% resolving el and autoradiographed. 
This autoradiogram is representative of an experiment performed twice 
with comparable r sults. 
itated was comparable under each condition, which excludes 
the possibillity that the changes in B-Raf activity could be due 
to variations in the B-Raf quantity present in the experiments 
(data not shown). The results in Fig. 5 demonstrate hat the 
NGF-induced B-Raf phosphorylation is activating since it ena- 
bles MEK-1 to phosphorylate and stimulate p44 m~pk. Indeed, 
B-Raf from NGF-treated cells induced a 2.3-fold activation of 
MEK-1 and of p44 m~pk. While CPT-cAMP alone had no effect, 
it inhibited the NGF-induced activation to the level observed 
in basal conditions. These results how that, similar to Raf-l, 
B-Raf can function as an activator of MEK-1. In a very recent 
study Traverse and Cohen reported that B-Raf activity can be 
measured only after B-Raf aggregation obtained after a 4 week- 
long storage of the protein at 4°C [23]. Here we show that 
freshly isolated B-Raf is endowed with enzymatic activity to- 
ward MEK-I. 
It should be noted that the activity of B-Raf obtained from 
untreated cells is elevated (Figs. 4 and 5). This may be related 
to the finding that Raf-1 is activated through phosphorylation 
of Tyr-340 and Tyr-341 after activation of the PDGF receptor, 
and in p60 ..... -transformed fibroblasts [24]. Moreover, muta- 
tion of these amino acids to negatively charged residues (Asp) 
has been shown to activate the catalytic activity of Raf-1 [24]. 
The sequence alignment of the catalytic domain for the Raf 
proteins revealed that all Raf-1 and A-Raf proteins have tyro- 
sine residues at positions analogous to Tyr-340 and Tyr-341, 
while B-Raf has negatively charged amino acids at these posi- 
tions. This difference in the amino acid sequence could render 
B-Raf 'constitutively active' as compared to Raf-l, and could 
explain, at least in part, the high basal activity of B-Raf. It could 
be envisioned that to restrain the 'unstimulated' MEK and 
MAPK, the high 'basal' activity of B-Raf toward MEK- 1 must 
be negatively regulated by phosphatases at the level of MEK 
and/or MAP kinase, as we previously suggested [25]. 
cAMP inhibits B-Raf activation as illustrated by the repres- 
sive action of CPT-cAMP on the NGF response (Figs. 4 and 
5). It has recently been reported that PKA phosphorylates 
Raf-1 on Ser-43 [8,10], and that this phosphorylation results in 
a profound inhibition of Ras binding which is necessary for 
Raf-1 activation [8 10]. Moreover, in their study, Chuang et al. 
demonstrated that this Ser-43 is located in a 50-amino acid 
PKA regulatory segment which is found only in Raf-1, and not 
in A-Raf or B-Raf[10]. In contrast, B-Raf possesses two poten- 
tial phosphorylation sites for PKA in its C-terminus, upstream 
of the kinase domain (Ser-429 in a RKSS sequence, and Ser-446 
in a RRDS sequence). To determine whether B-Raf is indeed 
a direct substrate of PKA, we performed an in vitro phospho- 
rylation experiment. Thus, B-Raf was immunopurified from 
PC12 cells, then incubated in the presence or absence of puri- 
fied PKA catalytic subunit without or with the protein kinase 
inhibitor, PKI. As observed in Fig. 6, PKA was able to phos- 
phorylate B-Raf, and this phosphorylation appears to be spe- 
cific since it was inhibited by PKI. Next, we tried to determine 
whether B-Raf associates with Ras, and whether this associa- 
tion was modified after CPT-cAMP treatment of PC12 cells. 
A reconstitution experiment was performed as described in 
PC 12 
treatment: I Buffer - ~  I - -  CPT 
214 
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Fig. 7. B-Raf association with p21 ""-~a~. PCI2 cells were treated with 
buffer or CPT-cAMP for 15 rain then solubilized. Cell extracts were 
incubated in the presence of Sepharose beads associated with heat- 
denaturated p21 n ..... (denaturated Ras), or with p21 n ..... loaded with 
GDP (Ras-GDP), or GTPyS (Ras-GTPyS). After 3 h at 4°C, beads 
were washed and the presence ofB-Raf associated with p21H ..... was 
determined asdescribed insection 2. This autoradiogram is representa- 
tive of an experiment performed 4 times with comparable r sults. 
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section 2, and the results are shown in Fig. 7. It was found that 
B-Raf associates with Ras-GTPTS, but not with heat-denatu- 
rated Ras and only very weakly with Ras-GDP. Note that 
similar studies with Raf-1 have previously shown that, whereas 
Raf-1 associates preferentialy with Ras-GTPTS, it associates 
also, albeit with much lower affinity, with Ras-GDP [26,27]. 
Interestingly, when cells were treated with CPT-cAMP, the 
ability of B-Raf to bind to Ras was dramatically decreased. 
However, the activity of B-Raf obtained from untreated or 
NGF-stimulated cells was not modified upon its in vitro phos- 
phorylation by PKA. These data suggest hat the association 
of B-Raf with Ras is essential for B-Raf activation and that its 
interruption might be sufficient o explain the inhibition of 
PKA on B-Raf functioning. In addition, it is likely that the 
mechanism of B-Raf inhibition after CPT-cAMP treatment of 
PCI2 cells is the same as that previously observed for Raf-1. 
However, while we favour the idea that this effect is due to a 
direct phosphorylation of B-Raf by PKA, we can not exclude 
the action of another kinase which could be previously acti- 
vated by PKA. In summary, from our data taken together we 
draw the key conclusion that B-Raf appears to be subjected to 
the same regulatory mechanisms as Raf-1, concerning both its 
activation by Ras and its inhibition by PKA phosphorylation. 
The latter point is particularly intriguing since the PKA phos- 
phorylation sites are not found in the same domains in both Raf 
proteins. 
The stimulation of MAP kinase by cAMP seen in PCI2 cells 
implies that there exist mechanisms which are obviously able 
to overcome the reduced B-Raf function in PKA-treated cells. 
To explain the stimulatory action of cAMP on MAP kinase in 
PC12 cells, it could be hypothesized that cAMP, either through 
PKA or directly, interferes with negative modulators of MEK, 
such as phosphatases, or activates MEK kinase(s) distinct from 
the Raf kinases, such as MEKK identified by Lange-Carter and 
colleagues [28]. Indeed, PKA has been shown to regulate the 
Ser/Thr phosphatase PP1G [29], tyrosine phosphatase activities 
[30] and the tyrosine phosphatase PTP-PEST [31]. However, 
whereas the phosphorylation sites modulating MEK activity 
have been determined [32], no data on phosphatase(s) regulat- 
ing MEK are available. An emerging hypothesis uggests that 
Raf-I is not the major or sole MEK activator involved in 
growth factor activation of cells. This is supported by observa- 
tions made in Swiss 3T3 cells [33] and adipocytes [34,35] where 
MAP kinase stimulation can be dissociated from Raf-1 activa- 
tion. Further, in Rat la cells, expression of constitutively acti- 
vated v-ras and v-raf did not result in a marked change in MEK 
activity [36]. Finally, transfection of PC12 cells with activated 
Raf-1 did not induce significant increases in MAP kinase activ- 
ity [37]. As a whole, these data indicate that in PC12 cells, MAP 
kinase activation is probably not mediated solely by Raf ki- 
nases. This could explain why NGF and cAMP have antagonis- 
tic effects on B-Raf activation, while they act in synergy to 
stimulate MEK-I .  Clearly, additional MEK activator(s) remain 
to be identified in PC12 cells. In this context, enzymes of the 
MEK kinase family certainly offer a promising track for future 
research. Indeed, at least five isoforms have been reported and 
some, but not all, appear to be activated in response to growth 
factors [1]. It is possible that one of these MEK kinases is 
specific for PC12 cells and that it is activated by cAMP, thus 
explaining why the cAMP stimulatory action on MAP kinase 
appears to be restricted to PCI2 cells. 
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